# LIMNW (Liminatus Pharma, Inc.) - SEC EDGAR Financial Statements

> Liminatus Pharma, Inc. reported $3.40M in total assets and a net loss of $12.52M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/LIMNW
- Markdown: https://convexityos.com/fundamentals/LIMNW.md
- SEC CIK: 0001971387
- Reporting currency: USD
- Latest filing period: June 30, 2026
- Last synced: Nov 21, 2026, 05:10 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001971387&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$4.07M | Operating profit |
| Net Income | FY 2025 | -$12.52M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.26 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$9.98M | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | $3.02M | Total debt: $1.44M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Research & Development | -- | $2.69M |
| Total Operating Expenses | $2.97M | $3.33M |
| **Operating Income** | -$2.97M | -$3.33M |
| **EBITDA** | -$2.97M | -- |
| Interest Income | $77K | $123K |
| Interest Expense | $216K | $339K |
| **Net Income** | -$10.21M | -$3.55M |
| Basic EPS | -$0.43 | -$0.20 |
| **Diluted EPS** | -$0.43 | -$0.20 |
| Basic Shares Outstanding | 23.8M | 17.5M |
| Diluted Shares Outstanding | 23.8M | 17.5M |

### Income Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $600K | $400K | -- | -- | -- | -- | -- | $357K |
| Total Operating Expenses | $1.38M | $1.10M | $884K | $701K | $1.12M | $264K | -- | $543K |
| **Operating Income** | -$1.38M | -$1.10M | -$884K | -$701K | -$1.12M | -$264K | -$167K | -$543K |
| **EBITDA** | -$1.38M | -$1.10M | -- | -- | -- | -- | -- | -- |
| Interest Income | -- | -- | $0 | $0 | $24K | $52K | -- | $34K |
| Interest Expense | $19K | $19K | $19K | $19K | $62K | $116K | -- | $93K |
| **Net Income** | -$1.41M | -$1.12M | -$8.17M | -$1.82M | $113K | -$328K | -$230K | -$601K |
| Basic EPS | -$0.03 | -$0.03 | -- | -$0.07 | $0.00 | -$0.02 | -- | -$0.03 |
| **Diluted EPS** | -$0.03 | -$0.03 | -- | -$0.07 | $0.00 | -$0.02 | -- | -$0.03 |
| Basic Shares Outstanding | 48.4M | 36.0M | -- | 27.0M | 23.3M | 17.5M | -- | 17.5M |
| Diluted Shares Outstanding | 48.4M | 36.0M | -- | 27.0M | 23.3M | 17.5M | -- | 17.5M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $338K | $56K |
| **Cash & Short-Term Investments** | $338K | $56K |
| **Total Current Assets** | $501K | $5.28M |
| Property, Plant & Equipment, Net | $12K | $941 |
| **Total Non-Current Assets** | $12K | $127K |
| **Total Assets** | $513K | $5.41M |
| Short-Term Debt | $1.44M | $19.97M |
| **Total Current Liabilities** | $10.30M | $24.75M |
| **Total Non-Current Liabilities** | $29K | $0 |
| **Total Liabilities** | $10.33M | $24.75M |
| **Total Debt (incl. Leases)** | $1.44M | $19.97M |
| Common Stock | $2.7K | $1.8K |
| Retained Earnings | -$38.87M | -$28.67M |
| **Total Stockholders' Equity** | -$9.81M | -$19.34M |
| Total Equity | -$9.81M | -$19.34M |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.02M | $1.91M | $338K | $725K | $1.34M | $56K |
| **Cash & Short-Term Investments** | $3.02M | $1.91M | $338K | $725K | $1.34M | $56K |
| **Total Current Assets** | $3.39M | $2.78M | $501K | $1.20M | $1.78M | $5.28M |
| Property, Plant & Equipment, Net | $11K | $12K | $12K | $13K | $198 | $941 |
| **Total Non-Current Assets** | $11K | $12K | $12K | $139K | $126K | $127K |
| **Total Assets** | $3.40M | $2.79M | $513K | $1.34M | $1.91M | $5.41M |
| Short-Term Debt | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $19.97M |
| **Total Current Liabilities** | $3.04M | $2.89M | $10.30M | $2.86M | $10.52M | $24.75M |
| **Total Non-Current Liabilities** | $63K | $33K | $29K | $124K | $200K | $0 |
| **Total Liabilities** | $3.10M | $2.92M | $10.33M | $2.99M | $10.72M | $24.75M |
| **Total Debt (incl. Leases)** | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $19.97M |
| Common Stock | $5.6K | $4.8K | $2.7K | $2.7K | $2.6K | $1.8K |
| Retained Earnings | -$41.40M | -$40.00M | -$38.87M | -$30.70M | -$28.88M | -$28.67M |
| **Total Stockholders' Equity** | $301K | -$133K | -$9.81M | -$1.65M | -$8.81M | -$19.34M |
| Total Equity | $301K | -$133K | -$9.81M | -$1.65M | -$8.81M | -$19.34M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$10.21M | -$3.55M |
| Depreciation & Amortization | $1.8K | -- |
| **Operating Cash Flow** | -$9.96M | -$1.45M |
| Capital Expenditure | -$13K | -- |
| **Free Cash Flow** | -$9.98M | -- |
| **Investing Cash Flow** | -$788K | -$2.85M |
| **Financing Cash Flow** | $11.03M | $3.92M |
| **Net Change in Cash** | $281K | -$378K |

### Cash Flow Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.41M | -$1.12M | -$8.17M | -$1.82M | $113K | -$328K | -$230K | -$601K |
| Depreciation & Amortization | $468 | $518 | -- | -- | -- | -- | -- | -- |
| **Operating Cash Flow** | -$970K | -$2.02M | -$387K | -$601K | -$8.82M | -$159K | -$141K | -$206K |
| **Investing Cash Flow** | -- | -- | $0 | -$13K | -$200K | -$575K | -- | -- |
| **Financing Cash Flow** | $2.08M | $3.59M | $0 | $0 | $10.32M | $713K | -- | -- |
| **Net Change in Cash** | $1.11M | $1.57M | -$387K | -$614K | $1.30M | -$21K | $9.3K | $13K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Return on Assets (ROA) | -1990.4% | -65.6% |
| Current Ratio | 0.05x | 0.21x |
| Quick Ratio | 0.03x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -4165.9% | -- | -- | -- | -- | -- | -- | -- |
| Return on Assets (ROA) | -367.9% | -394.3% | -1990.4% | -168.9% | -54.8% | -- | -65.6% | -- |
| Current Ratio | 1.12x | 0.96x | 0.05x | 0.42x | 0.17x | -- | 0.21x | -- |
| Quick Ratio | 0.99x | 0.66x | 0.03x | 0.25x | 0.13x | -- | 0.00x | -- |
| Debt to Equity | 4.80x | -- | -- | -- | -- | -- | -- | -- |
| **Net Income Growth (YoY)** | -1342.2% | -- | -- | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
